Tocainida [INN-Spanish] en es it fr

Tocainida [INN-Spanish] Brand names, Tocainida [INN-Spanish] Analogs

Tocainida [INN-Spanish] Brand Names Mixture

  • No information avaliable

Tocainida [INN-Spanish] Chemical_Formula


Tocainida [INN-Spanish] RX_link

Tocainida [INN-Spanish] fda sheet

Tocainida_[INN-Spanish] FDA

Tocainida [INN-Spanish] msds (material safety sheet)

Tocainida_[INN-Spanish] MSDS

Tocainida [INN-Spanish] Synthesis Reference

No information avaliable

Tocainida [INN-Spanish] Molecular Weight

500.548 g/mol

Tocainida [INN-Spanish] Melting Point

No information avaliable

Tocainida [INN-Spanish] H2O Solubility

>16 mg/ml at 25.0°C

Tocainida [INN-Spanish] State


Tocainida [INN-Spanish] LogP


Tocainida [INN-Spanish] Dosage Forms

Sterile ophthalmic solution (0.004%) with a pH of approximately 6.0 and an osmolality of approximately 290 mosmol/kg.

Tocainida [INN-Spanish] Indication

Ophthalmic solution used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.

Tocainida [INN-Spanish] Pharmacology

Travoprost, an isopropyl ester prodrug, is a synthetic prostaglandin F analogue. Travoprost reduces pressure in the eye by increasing the amount of fluid that drains from the eye.

Tocainida [INN-Spanish] Absorption

Systemically absorbed when administered to the eye.

Tocainida [INN-Spanish] side effects and Toxicity

Symptoms of overexposure include irritation to the skin, eyes, nose, throat, and respiratory tract.

Tocainida [INN-Spanish] Patient Information

No information avaliable

Tocainida [INN-Spanish] Organisms Affected

Humans and other mammals